Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully treat HCV. Unfortunately, antiviral therapy fails in some patients, resulting in a relapse of HCV.

A study published in the Journal of Clinical Investigation identifies a marker that can identify patients likely to have an HCV relapse after . Shyamasundaran Kottilil and colleagues at the NIH evaluated the immune response of HCV-infected individuals treated with . Treated patients that had increased expression of type I interferon were more likely to remain HCV-free. Patients unable to maintain a type I interferon response were more likely to have an HCV relapse.

This study provides a potential marker to identify patients prone to HCV relapse. Moreover, these results suggest that type I interferon treatment in at-risk patients merits future study.

More information: Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome, J Clin Invest. DOI: 10.1172/JCI75938

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Researchers gain new insights into hypothyroidism

8 hours ago

An international research team led by physician-scientists at Rush University Medical Center has gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.